Imunon, Inc.
IMNN
$2.04
$0.020.99%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
6/4/2026
-
Seeking Alpha - Healthcare
6/4/2026
-
Globe Newswire
6/1/2026
-
Fool.com Headlines
5/14/2026
-
The Cerbat Gem
5/12/2026
-
TipRanks Financial Blog
5/12/2026
-
Seeking Alpha - Healthcare
5/12/2026
-
SeekingAlpha
5/12/2026
-
Nasdaq News: Markets
5/12/2026
-
Fool.com Headlines
5/12/2026
-
Globe Newswire
5/5/2026
-
Globe Newswire
4/4/2026
-
TipRanks Financial Blog
4/2/2026
-
Insider Monkey
3/31/2026
-
Seeking Alpha: Transcripts
3/31/2026
-
SeekingAlpha
3/31/2026
-
Globe Newswire
3/30/2026
-
Seeking Alpha - Healthcare
3/30/2026
-
SeekingAlpha.com: All News
3/25/2026
-
The Fly
3/25/2026
-
Globe Newswire
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
3/24/2026
-
Globe Newswire
3/23/2026
-
TipRanks Financial Blog
3/23/2026
-
TipRanks Financial Blog
2/5/2026
-
The Fly
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Tuesday, March 31, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 11 and 15 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
609 896 9100
Address
997 Lenox Drive
Lawrenceville, NJ 08648
Lawrenceville, NJ 08648
Country
Year Founded
Business Description
Sector
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company’s lead clinical program is IMNN-001, a DNA-based...
more